Quarterly report pursuant to Section 13 or 15(d)

Recent Developments, Liquidity and Management???s Plans (Details Narrative)

v3.21.2
Recent Developments, Liquidity and Management’s Plans (Details Narrative)
 3 Months Ended 4 Months Ended 9 Months Ended
Apr. 16, 2021
USD ($)
shares
Apr. 16, 2021
USD ($)
shares
Sep. 30, 2021
USD ($)
Jun. 30, 2021
USD ($)
Mar. 31, 2021
USD ($)
Sep. 30, 2020
USD ($)
Jun. 30, 2020
USD ($)
Mar. 31, 2020
USD ($)
Apr. 15, 2021
shares
Sep. 30, 2021
USD ($)
d
$ / shares
shares
Sep. 30, 2020
USD ($)
Dec. 31, 2020
USD ($)
Mar. 23, 2020
Dec. 31, 2019
USD ($)
Nov. 30, 2019
USD ($)
Cash and Cash Equivalents, at Carrying Value     $ 1,375,014             $ 1,375,014   $ 148,284      
[custom:DescriptionOfContributionTransaction] cause Cystron to contribute substantially all of the assets associated with its business or developing and manufacturing Cystron’s COVID-19 vaccine candidate to Oravax. In consideration for the Company’s commitment to consummate the Contribution Transaction, Oravax issued to the Company                            
Royalty payments, percentage 0.025                            
Accounts Payable, Current     2,053,542             2,053,542   1,801,729      
Amounts paid by related party                   3,062,444        
Goodwill     10,498,539             $ 10,498,539        
Debt Instrument, Convertible, Threshold Consecutive Trading Days | d                   10          
Debt Instrument, Redemption, Description                   Milestone Shares to be issued be deemed to be less than $5.00 per share          
Marketable Securities, Current     14,002,767             $ 14,002,767        
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest     5,467,281     $ 3,122,900       26,649,321 5,199,758        
[custom:WorkingCapital-0]     13,855,132             13,855,132          
Stockholders' Equity Attributable to Parent     25,891,924 $ 31,074,335 $ (8,346,738) (3,765,816) $ (3,051,439) $ (2,664,780)   25,891,924 (3,765,816) (5,257,034)   $ (2,332,831.00) $ (1,726,363)
Retained Earnings (Accumulated Deficit)     75,321,846             75,321,846   $ 48,672,525      
Net Cash Provided by (Used in) Operating Activities                   14,704,008 3,415,364        
Net Income (Loss) Attributable to Parent     5,467,281 $ 18,092,336 $ 3,089,704 $ 3,122,900 $ 1,094,909 $ 981,949   26,649,321 5,199,758        
Increase (Decrease) in Accounts Payable, Trade                   3,233,299 $ 26,142        
Share-based Payment Arrangement, Noncash Expense                   $ 15,036,051          
MyMD Pharmaceuticals (Florida), Inc [Member]                              
Shares issued for acquistion | shares 32,741,622                            
Restricted Stock Units (RSUs) [Member]                              
Shares vested | shares                 394,680 263,026          
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value | $ / shares                   $ 4.94          
Oravax [Member]                              
Accounts Payable, Current     1,500,000             $ 1,500,000          
Premas [Member]                              
Accounts Payable, Current     300,000             300,000          
Contribution Agreement [Member]                              
Cash and Cash Equivalents, at Carrying Value $ 1,500,000 $ 1,500,000                          
Common Stock, Capital Shares Reserved for Future Issuance | shares 390,000 390,000                          
Contribution Agreement [Member] | Premas Biotech PVT Ltd. [Member]                              
Due to related parties     $ 1,500,000             1,500,000          
Contribution Agreement [Member] | Pre-merger Akers Biosciences, Inc. [Member]                              
Amounts paid by related party                   $ 1,200,000          
Merger Agreement [Member]                              
Issuance of post reverse stock split | shares 28,553,307                            
Exchange ratio percentage   77.05%                          
Percentage of common stock 49.68% 49.68%                          
Merger Agreement [Member] | Pre-funded Warrants [Member]                              
Warrants to purchase | shares 986,486 986,486                          
Cystron Biotech LLC [Member] | Membership Interest Purchase Agreement [Member]                              
Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage                         100.00%    
MYMD Pharmaceuticals, Inc., [Member] | Merger Agreement [Member]                              
Business acquisition description Upon completion of the Merger and the transactions contemplated in the Merger Agreement, the Company issued 28,553,307 post reverse stock split shares of Company Common Stock to the former stakeholders of pre-Merger MyMD Florida at the Exchange Ratio. Upon completion of the Merger and the transactions contemplated in the Merger Agreement, the former stakeholders of pre-Merger MyMD Florida held approximately 77.05% of the Company’s Common Stock outstanding on a fully diluted basis, assuming the exercise in full of the pre-funded warrants to purchase 986,486 shares of Company Common Stock and including 4,188,315 shares of Company Common Stock underlying options to purchase shares of pre-Merger MyMD Florida Common Stock assumed by the company at closing and after adjustments based on the Company’s net cash at closing. Holders of pre-Merger common stock of the Company held approximately 22.95% of the outstanding equity of the Company. Also upon completion of the Merger and the transactions contemplated by the Merger Agreement, the Company assumed 4,188,315 MyMD Florida stock options subject to certain terms contained in the Merger Agreement (including, but not limited to, the amendment of such stock option to extend the term of such stock option for a period expiring on April 16, 2023, the second-year anniversary of the Merger.                            
Akers Biosciences, Inc [Member]                              
Business acquisition description                   Akers’ valuation is based upon 8,335,627 common shares outstanding and 263,026 vested restricted stock units (“RSU’) with a fair market value of $4.94 per share, the closing price of Akers common shares on the NASDAQ Stock Exchange on April 16, 2021.          
Goodwill $ 10,498,539 $ 10,498,539                          
Pre market capitalization 42,477,346 42,477,346                          
Tangible asset $ 31,978,807 $ 31,978,807                          
Shares issued for acquistion | shares                   8,335,627